Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DAP000280

Drug Information
NameBrimonidine
SynonymsNCGC00023468-04; 5-brom-n-(4,5-dihydro-1h-imidazol-2-yl)chinoxalin-6-amin; ZINC21303210; U104_SIGMA; MLS001076349; AC-162; UK 14,304-18; Brimonidine [INN:BAN]; MLS000069370; CID2435; UK 14308; NCGC00023468-07; L000615; NCGC00016069-01; AR-1G7332; SAM002548958; 5-Bromo-6-(2-imidazolin-2-ylamino)quinoxaline; Tocris-0425; Lopac0_001216; UK 14304; U-104; Bromoxidine; NCGC00023468-05; 59803-98-4; 70359-46-5 (tartrate[1:1]); 5-bromo-6-(imidazolidinylideneamino)quinoxaline; 6-Quinoxalinamine, 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)- (9CI); PDSP1_000640; 5-Bromo-N-(2-imidazolin-2-yl)-6-quinoxalinamine; 6-Quinoxalinamine, 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-; 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine; Brimonidine (INN); AC1Q26LW; nchembio705-7; FT-0082636; NCGC00016069-02; C11H10BrN5; 5-bromo-6-(imidazolin-2-ylamino)quinoxaline; UK 14304-18; UNII-E6GNX3HHTE; brimonidina; NCGC00016069-06; CPD000058355; AGN 190342; LK 14304-18; CHEMBL844; NCGC00023468-02; D07540; brimonidinum; Lopac-U-104; CHEBI:3175; BRN 0751629; T6531398; UK 14,304; BIDD:GT0649; NSC318825; DB00484; MolPort-003-959-841; 5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-6-quinoxalinamine; NCGC00016069-11; AGN-190342; AC1L1DO5; C07886; UK-14,304-18; PDSP2_000635; NCGC00023468-06; LS-142950; SMR000058355; AC1Q24IC; UK-14304; brimonidine; EU-0101216; UK-14,308
Trade NameAlphagan; Alphagan-P
CompanyAllergan Pharmaceuticals
IndicationOpen-angle glaucoma and ocular hypertension
[ICD9: 365, 365.04   ICD10: H40-H42, H40.0]
Approved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C11H10BrN5/c12-9-7(17-11-15-5-6-16-11)1-2-8-10(9)14-4-3-13-8/h
1-4H,5-6H2,(H2,15,16,17)
InChIKeyXYLJNLCSTIOKRM-UHFFFAOYSA-N
Canonical SMILESC1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br    
Therapeutic ClassAntihypertensive Agents
CAS NumberCAS 59803-98-4
FormulaC11H10BrN5
PubChem Compound IDCID 2435.
PubChem Substance IDSID 10088.
ChEBI3175;
SuperDrug ATC IDD11AX21; S01EA05
SuperDrug CAS ID059803984;
TargetAlpha-2A adrenergic receptorAgonist[2][3][4]
Ref 1Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20. To Reference
Ref 2alpha(2A)-adrenoceptor: G(alphai1) protein-mediated pertussis toxin-resistant attenuation of G(s) coupling to the cyclic AMP pathway. Biochem Pharmacol. 2000 Jun 15;59(12):1531-8. To Reference
Ref 3Potent alpha(2A)-adrenoceptor-mediated vasoconstriction by brimonidine in porcine ciliary arteries. Invest Ophthalmol Vis Sci. 2001 Aug;42(9):2049-55. To Reference
Ref 4Decreased density of presynaptic alpha 2-adrenoceptors in postmortem brains of patients with Alzheimer's disease. J Neurochem. 1992 May;58(5):1896-904. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543